Off-the-Shelf Allogeneic Cell Therapy in Autoimmune Diseases & Cancers
Time: 1:30 pm
day: Day One - Track B PM
Details:
- Optimizing γ CAR-T manufacturing processes to produce ~1,000 doses with high purity and CAR expression
- Discussing how γ CAR-T products with armored CAR design achieves comparable tumor serial killing in vitro and superior tumor clearance in vivo compared to γγ CAR-T
- In vivo CAR-T therapy by T cell-targeted LNP delivery achieves complete Nalm-6 tumor control in a mouse model
